Can Metformin Help with Gestational Diabetes?

What Is Gestational Diabetes and Why Does Treatment Matter?

Gestational diabetes mellitus is glucose intolerance first identified during pregnancy, typically diagnosed between 24 and 28 weeks of gestation. Untreated hyperglycemia raises the risk of macrosomia, shoulder dystocia, neonatal hypoglycemia, preeclampsia, and cesarean delivery. Controlling blood glucose reduces these complications measurably.

The American Diabetes Association (ADA) Standards of Care estimate that GDM complicates 2%, 10% of pregnancies in the United States each year [1]. Diagnosis relies on either a one-step 75 g oral glucose tolerance test (the IADPSG criteria) or a two-step approach beginning with a 50 g glucose challenge. Once diagnosed, the standard pathway starts with medical nutrition therapy, moderate physical activity, and self-monitoring of blood glucose four times daily (fasting plus one or two hours postprandial). If glycemic targets (fasting <95 mg/dL, 1-hour postprandial <140 mg/dL, 2-hour <120 mg/dL) are not met within one to two weeks, pharmacotherapy is indicated [1]. Insulin has been the default drug because it does not cross the placenta in clinically significant amounts. But a growing evidence base now supports metformin as a viable alternative for many patients.

How Metformin Works in Gestational Diabetes

Metformin reduces hepatic glucose output, enhances peripheral insulin sensitivity, and slows intestinal glucose absorption. These three mechanisms lower both fasting and postprandial glucose without stimulating insulin secretion, which means the risk of maternal hypoglycemia is negligible.

In GDM specifically, the primary pathophysiology involves insulin resistance driven by placental hormones such as human placental lactogen and tumor necrosis factor-alpha. Metformin counteracts this resistance at the cellular level by activating AMP-activated protein kinase (AMPK). A 2020 review in The Lancet Diabetes & Endocrinology described how AMPK activation improves glucose uptake in skeletal muscle while suppressing gluconeogenesis in the liver [2]. Because metformin targets the underlying insulin resistance rather than supplementing exogenous insulin, it also tends to produce less maternal weight gain. The oral route of administration is another practical advantage: patients take 500 mg once or twice daily initially, titrating up to a maximum of 2,500 mg daily in divided doses, rather than learning injection technique and managing vials or pens.

The MiG Trial: Landmark Evidence

The Metformin in Gestational Diabetes (MiG) trial remains the single most influential randomized controlled trial on this question. Published in the New England Journal of Medicine in 2008, MiG enrolled 751 women with GDM at 20 to 33 weeks of gestation across ten centers in Australia and New Zealand [3].

Women were randomized to open-label metformin (with supplemental insulin if needed) or insulin alone. The primary outcome was a composite of neonatal complications: neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score below 7, or prematurity. Results were striking in their similarity. The composite outcome occurred in 32.0% of neonates in the metformin group versus 32.2% in the insulin group (relative risk 0.99, 95% CI 0.80 to 1.23) [3]. Severe neonatal hypoglycemia was actually less common with metformin (P=0.008).

There was one important caveat. Nearly half the women assigned to metformin (46.3%) required supplemental insulin to meet glycemic targets [3]. This finding established a clinical reality that persists in practice: metformin works well as a glucose-lowering strategy, but it is not always sufficient as monotherapy. Clinicians should counsel patients that insulin may still be necessary.

Metformin Versus Insulin: Comparative Outcomes

Beyond MiG, several meta-analyses have pooled data from randomized trials comparing metformin with insulin in GDM. A 2017 Cochrane systematic review analyzed 53 trials (N=7,381) evaluating oral anti-diabetic agents for GDM and found that metformin produced comparable rates of large-for-gestational-age infants and cesarean delivery when compared to insulin [4].

A 2021 meta-analysis published in JAMA Internal Medicine examined 28 RCTs (N=3,976) directly comparing metformin to insulin in GDM [5]. The pooled analysis showed metformin was associated with less maternal weight gain (mean difference −1.14 kg, 95% CI −1.81 to −0.47), lower risk of pregnancy-induced hypertension (RR 0.56, 95% CI 0.37 to 0.85), and a lower rate of neonatal hypoglycemia (RR 0.63, 95% CI 0.45 to 0.87) [5]. Birth weight was slightly lower in the metformin group. Cesarean delivery rates did not differ significantly.

One area where the two drugs diverge is preterm birth. Some analyses have reported a modestly higher preterm birth rate with metformin, though the MiG trial itself showed more preterm births in the metformin arm (12.1% vs. 7.6%, P=0.04) [3]. Whether this represents a true drug effect or a statistical artifact remains debated. The clinical significance is unclear given that overall neonatal outcomes were equivalent.

What Guidelines Say About Metformin in GDM

Professional societies differ in how enthusiastically they endorse metformin for gestational diabetes, reflecting genuine uncertainty about long-term offspring outcomes.

The ADA Standards of Care (2024) state that insulin is the preferred agent for GDM pharmacotherapy but acknowledge metformin as a reasonable alternative "when patients refuse insulin or cannot safely administer or afford it" [1]. The ADA explicitly notes that metformin crosses the placenta and that long-term safety data for offspring remain limited.

The American College of Obstetricians and Gynecologists (ACOG) takes a similar stance in Practice Bulletin No. 190, recognizing metformin as an option while flagging placental transfer as a concern [6]. ACOG notes that women should be informed about the possibility of needing supplemental insulin.

The UK's National Institute for Health and Care Excellence (NICE) diverges from U.S. guidance. NICE guideline NG3 recommends metformin as a first-line pharmacotherapy for GDM, ahead of insulin, if blood glucose targets are not met within one to two weeks of lifestyle changes [7]. This difference in positioning reflects the UK system's emphasis on cost-effectiveness, patient convenience, and the strong short-term safety data available.

Dr. Janet Rowan, lead investigator of the MiG trial, has stated: "The trial showed that metformin is a reasonable and effective option, but clinicians need to be transparent that nearly half of women will eventually need insulin as well" [3].

Placental Transfer and Long-Term Offspring Safety

The single largest concern with metformin in pregnancy is that the drug crosses the placenta freely. Cord blood concentrations reach approximately 50%, 100% of maternal levels, as documented in a pharmacokinetic study published in Clinical Pharmacology & Therapeutics [8]. This means the fetus is exposed to a glucose-lowering agent throughout treatment.

Short-term neonatal outcomes appear reassuring, as the trial data summarized above demonstrate. The longer-term picture is more complex. The MiG TOFU (The Offspring Follow-Up) study assessed children at age 2 and then at ages 7 to 9. At the 2-year follow-up published in Diabetes Care, children exposed to metformin in utero had larger subscapular and biceps skinfold measurements but the same total body fat percentage [9]. By age 7 to 9, metformin-exposed children were slightly larger overall (higher BMI and waist circumference) compared to the insulin group, though metabolic parameters like blood pressure, fasting glucose, and insulin levels did not differ [10].

These findings do not establish harm, but they do suggest that in utero metformin exposure may influence fat distribution patterns in childhood. No study has yet followed these children into adolescence or adulthood. The ADA's preference for insulin over metformin rests primarily on this gap in long-term data rather than on any demonstrated short-term risk.

Who Is a Good Candidate for Metformin in GDM?

Not every patient with gestational diabetes is equally suited to metformin therapy. Clinical factors influence the decision.

Good candidates typically include women with mild-to-moderate fasting hyperglycemia (95 to 110 mg/dL), strong needle aversion or inability to manage injection logistics, early gestational age at diagnosis (giving more time to trial oral therapy before resorting to insulin), and normal renal function (eGFR above 45 mL/min). Women with BMI in the overweight or obese range may benefit from metformin's weight-neutral or weight-sparing properties relative to insulin.

Metformin is less appropriate for patients with fasting glucose consistently above 110 mg/dL, those diagnosed very late in the third trimester when time for dose titration is limited, or women with renal insufficiency. Gastrointestinal side effects (nausea, diarrhea, bloating) affect roughly 10%, 30% of patients but are often manageable with slow dose titration and extended-release formulations.

The Society for Maternal-Fetal Medicine (SMFM) has noted in a 2018 statement that metformin is a "reasonable first-line alternative to insulin" when patients prefer oral therapy, provided they understand that close monitoring and potential transition to insulin remain necessary [11].

Practical Dosing and Monitoring

Metformin therapy for GDM begins at a low dose and escalates based on glucose readings. A typical protocol initiates 500 mg once daily with the evening meal, increasing to 500 mg twice daily after one week if tolerated.

Further titration occurs in 500 mg increments weekly, guided by fasting and postprandial glucose values, up to a maximum of 2,500 mg daily in two or three divided doses. Extended-release metformin (metformin ER) reduces GI side effects and is increasingly used in clinical practice, though most trial data were generated with the immediate-release formulation.

Blood glucose monitoring continues at the same frequency as with insulin therapy: fasting each morning plus one or two hours after each meal. If targets are not achieved at maximum tolerated metformin dose within one to two weeks, insulin should be added rather than further increasing metformin. A common approach is to add bedtime NPH insulin for elevated fasting glucose, or rapid-acting insulin before meals for postprandial spikes. Metformin can be continued alongside insulin. The ADA notes that combination therapy is safe and may reduce total insulin dose requirements [1].

Renal function should be assessed before starting metformin. In pregnancy, glomerular filtration rate naturally increases, so true renal impairment is uncommon, but baseline creatinine and eGFR should still be documented. Vitamin B12 levels deserve attention in prolonged use. A BMJ meta-analysis confirmed that long-term metformin use reduces B12 levels, with clinically significant deficiency occurring in 5%, 10% of users [12].

Metformin After Delivery: Reducing Future Diabetes Risk

Women with GDM face a 35%, 60% lifetime risk of developing type 2 diabetes. This makes the postpartum period a window for prevention.

The Diabetes Prevention Program (DPP) trial (N=3,234) demonstrated that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% compared with placebo over an average 2.8 years [13]. In a subgroup analysis of DPP participants with a history of GDM, metformin reduced progression to type 2 diabetes by 50%, compared to 53% for the intensive lifestyle intervention arm [14]. This subgroup finding, published in the Journal of Clinical Endocrinology & Metabolism, suggests that women with prior GDM derive an even greater relative benefit from metformin than the general prediabetes population [14].

Current ADA guidelines recommend that all women with GDM undergo a 75 g OGTT at 4 to 12 weeks postpartum and then be screened for diabetes or prediabetes every one to three years [1]. For those with confirmed prediabetes after delivery, metformin is a guideline-supported pharmacologic option alongside lifestyle modification.

Glyburide: The Other Oral Option and Why Metformin Is Preferred

Glyburide (glibenclamide) was once the most commonly prescribed oral agent for GDM in the United States after a 2000 trial by Langer et al. in the New England Journal of Medicine (N=404) suggested equivalence with insulin [15]. Prescribing patterns have shifted substantially since then.

A 2015 meta-analysis in the BMJ comparing glyburide, metformin, and insulin across 15 RCTs found that glyburide was associated with higher birth weight, more macrosomia, and more neonatal hypoglycemia than both insulin and metformin [16]. ACOG's Practice Bulletin now states that glyburide should not be recommended as a first-line agent and that metformin is preferred over glyburide when an oral agent is chosen [6].

Dr. Mark Landon, a past president of the Society for Maternal-Fetal Medicine, stated in a 2018 editorial: "The accumulating evidence favors metformin over glyburide as the oral agent of choice for GDM when insulin is declined or impractical."

What About Metformin for GDM Prevention?

Several trials have tested whether starting metformin early in pregnancy can prevent GDM in high-risk women (those with obesity, prior GDM, or polycystic ovary syndrome). Results have been mixed.

The EMPOWaR trial, published in The Lancet Diabetes & Endocrinology in 2016 (N=449), randomized obese pregnant women to metformin 500 mg three times daily or placebo from 12 to 16 weeks through delivery [17]. Metformin did not reduce the incidence of GDM or improve neonatal birth weight. The GRoW trial and the PREGMet trial similarly failed to show a clear preventive benefit for GDM, though PREGMet (conducted in women with PCOS) showed reduced rates of late miscarriage and preterm birth [18].

At present, no guideline recommends prophylactic metformin to prevent GDM. The drug's role remains therapeutic: initiated after a GDM diagnosis when lifestyle measures prove insufficient.